Aprecia announced that Spritam (levetiracetam) tablets for oral suspension are now available as adjunctive therapy in the treatment of partial-onset seizures in patients ≥4 years old, myoclonic seizures in patients ≥12 years old, and primary generalized tonic-clonic seizures in patients ≥6 years old.
Spritam is the first prescription product approved by the Food and Drug Administration (FDA) that is developed using 3D printing technology. It is formulated using the Company’s proprietary ZipDose Technology that combines precise 3D printing and formulation science to produce rapidly disintegrating formulations of medicines. The product disintegrates in the mouth with a sip of liquid (mean time of 11 seconds), giving patients with swallowing difficulties a new option. The tablets may also be added to a small volume of liquid and consumed after dispersion.
The exact mechanism by which levetiracetam exerts its antiepileptic effect is unknown. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, suggesting that levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity.
Spritam is available as 250mg, 500mg, 750mg, and 1000mg spearmint-flavored tablets in 60-count cartons.
For more information call (844) 882-7732 or visit Spritam.com.